Skip to content

A real-world retrospective cohort study on the efficacy of Gouteng Laifuzi Decoction in the treatment of hypertension

A real-world retrospective cohort study on the efficacy of Gouteng Laifuzi Decoction in the treatment of hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025000347
Enrollment
Unknown
Registered
2025-02-19
Start date
2025-02-26
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Control group:none
Exposure group:Gouteng Laifuzi Decoction

Sponsors

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for hypertension, refer to the diagnostic criteria of the 2024 "Revised Edition of the Guidelines for the Prevention and Treatment of Hypertension in China", that is, without the use of antihypertensive drugs, measure blood pressure three times on different days, and the systolic blood pressure is =140mmHg and (or) the diastolic blood pressure is =90mmHg. Systolic blood pressure =140mmHg and diastolic blood pressure <90mmHg is isolated systolic hypertension. Patients with a history of hypertension and currently taking antihypertensive drugs are also diagnosed with hypertension even if their blood pressure is lower than 140/90mmHg. (2) Age over 18 years old, regardless of gender. (3) Complete electronic medical record data

Exclusion criteria

Exclusion criteria: (1) Patients with secondary hypertension, refractory hypertension, malignant hypertension, acute and subacute hypertension, white coat hypertension and unstable blood pressure. (2) Pregnant and lactating women, and women of childbearing age who do not agree to take contraceptive measures during the trial. (3) Those with mental illness and who cannot cooperate well. (4) Those who are confirmed to have severe heart disease, severe neurosis and heart, liver and kidney dysfunction after examination. (5) Patients with severe primary diseases such as endocrine, hematopoietic system, liver and kidney, malignant tumors and mental illness. (6) Patients with uncorrected hyperthyroidism, hypothyroidism; patients with nephrotic syndrome, diabetes and acute hepatobiliary disease. (7) Those who have suffered from severe cerebrovascular accident, heart disease, severe trauma, major surgery within 6 months and other primary diseases with unstable general condition and poor prognosis.

Design outcomes

Primary

MeasureTime frame
blood pressure;

Countries

China

Contacts

Public ContactLi Yunlun

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine

li.yunlun@163.com13869102760

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026